Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

被引：29
|
作者：
Merseburger, Axel S. [1 ]
Bellmunt, Joaquim [2 ]
Jenkins, Cheryl [3 ]
Parker, Chris [4 ]
Fitzpatrick, John M. [5 ,6 ]
机构：
[1] Hannover Med Sch, Dept Urol & Urol Oncol, D-30625 Hannover, Germany
[2] Univ Hosp Mar, Inst Invest Med, Med Oncol Serv, Barcelona, Spain
[3] Rocket Sci Med Commun, Wantage, Oxon, England
[4] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton, Surrey, England
[5] Mater Misericordiae Hosp Univ Coll, Dept Surg, Dublin, Ireland
[6] Irish Canc Soc, Dublin, Ireland
来源：
ONCOLOGIST | 2013年 / 18卷 / 05期
关键词：
Metastatic castration-resistant; Prostate cancer; Treatment; Docetaxel; Cabazitaxel; Abiraterone acetate; Enzalutamide; CIRCULATING TUMOR-CELLS; ANDROGEN RECEPTOR GENE; MITOXANTRONE PLUS PREDNISONE; PHASE-II TRIAL; CLINICAL-TRIALS; BONE METASTASES; SIPULEUCEL-T; SKELETAL COMPLICATIONS; ABIRATERONE ACETATE; INCREASED SURVIVAL;
D O I：
10.1634/theoncologist.2012-0478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
引用
收藏
页码：558 / 567
页数：10
相关论文
共 50 条
  • [41] Castration-resistant metastatic prostate cancer: current status and treatment possibilities
    Carles, Joan
    Castellano, Daniel
    Angel Climent, Miguel
    Maroto, Pablo
    Medina, Rafael
    Alcaraz, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (03): : 169 - 176
  • [42] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Zafar Malik
    Heather Payne
    Jawaher Ansari
    Simon Chowdhury
    Mohammad Butt
    Alison Birtle
    Santhanam Sundar
    Chinnamani Vee Eswar
    Simon Hughes
    Amit Bahl
    Advances in Therapy, 2013, 30 : 1041 - 1066
  • [43] Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer
    Mourmouris, Panagiotis
    Papatsoris, Athanasios
    Dellis, Athanasios
    Mitsogiannis, Iraklis
    Abou Chakra, Mohamed
    Moussa, Mohamad
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (15) : 1955 - 1959
  • [44] Treatment-induced Treatment Sensitization in Metastatic Castration-resistant Prostate Cancer
    Gupta, Shilpa
    Heemers, Hannelore V.
    EUROPEAN UROLOGY, 2021, 79 (06) : 734 - 735
  • [45] Androgen receptor antagonist Treatment of metastatic castration-resistant prostate cancer Treatment of metastatic breast cancer
    Culig, Zoran
    DRUGS OF THE FUTURE, 2023, 48 (01) : 15 - 21
  • [46] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667
  • [47] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Sandhu, Shahneen
    Chi, Kim N.
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Roubaud, Guilhem
    Ozguroglu, Mustafa
    Kang, Jinyu
    Burgents, Joseph
    Gresty, Christopher
    Corcoran, Claire
    Adelman, Carrie A.
    de Bono, Johann
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24): : 2345 - 2357
  • [48] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648
  • [49] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [50] Re: Olaparib for Metastatic Castration-resistant Prostate Cancer
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2020, 78 (05) : 767 - 768
12345